Henlius Biotech wins shareholder approval for Star dual listing
Hong Kong-listed Shanghai Henlius Biotech got the go ahead from its controlling shareholders on Monday for a secondary flotation on China’s Star Market.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: